4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Takeda Pharmaceutical Company Limited (4502) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Chuo, Japan with about 47,029 employees. Its market capitalization is roughly JPY 8.91 trillion. In the fiscal year ended 2026-03-31, 4502 reported JPY 4.51T in revenue and (JPY 152.4B) in net income.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue | JPY 4.51T | JPY 4.58T | JPY 4.26T | JPY 4.03T |
| Gross Profit | JPY 2.93T | JPY 3.00T | JPY 2.84T | JPY 2.78T |
| Operating Income (EBIT) | JPY 464.5B | JPY 466.4B | JPY 309.9B | JPY 587.8B |
| Net Income | (JPY 152.4B) | JPY 107.9B | JPY 144.1B | JPY 317.0B |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|---|
| Total Revenue | JPY 1.22T | JPY 1.09T | JPY 1.19T | JPY 1.11T | JPY 1.11T |
| Gross Profit | JPY 813.2B | JPY 688.8B | JPY 790.5B | JPY 732.7B | JPY 722.0B |
| Operating Income (EBIT) | JPY 201.4B | JPY 42.1B | JPY 168.8B | JPY 69.0B | JPY 184.6B |
| Net Income | JPY 113.2B | (JPY 368.5B) | JPY 103.6B | (JPY 11.8B) | JPY 124.2B |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (JPY 311.9B) | (JPY 302.5B) | (JPY 287.2B) | (JPY 279.4B) | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Dividends Paid | — | (JPY 8.8B) | (JPY 149.0B) | (JPY 8.8B) | (JPY 145.3B) | (JPY 9.7B) |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | JPY 15.51T | JPY 14.25T | JPY 15.11T | JPY 13.96T | — |
| Total Liabilities | JPY 8.08T | JPY 7.31T | JPY 7.83T | JPY 7.60T | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 4502 viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms